Advertisement
Advertisement
ILMN
Illumina Inc
119.63
USDSponsored
-13.98
-10.46%
Feb 06, 15:59 UTC -5
Closed
After-Market
119.69
+0.05
+0.05%
ILMN Earnings Reports
Positive Surprise Ratio
ILMN beat 32 of 40 last estimates.
80%
Next Report
Date of Next Report
May 06, 2026
Estimate for Q1 26 (Revenue/ EPS)
$1.08B
/$1.15
Implied change from Q4 25 (Revenue/ EPS)
-6.71%
/-14.81%
Implied change from Q1 25 (Revenue/ EPS)
+3.86%
/+18.56%
Illumina Inc earnings per share and revenue
On Feb 05, 2026, ILMN reported earnings of 1.35 USD per share (EPS) for Q4 25, beating the estimate of 1.24 USD, resulting in a 8.01% surprise. Revenue reached 1.16 billion, compared to an expected 1.12 billion, with a 3.05% difference. The market reacted with a -10.40% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 18 analysts forecast an EPS of 1.15 USD, with revenue projected to reach 1.08 billion USD, implying an decrease of -14.81% EPS, and decrease of -6.71% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
Adaptive Biotechnologies Corporation Common Stock
Report Date
Feb 05, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.09
Surprise
+51.33%
AYTU BioPharma, Inc. Common Stock
Report Date
Feb 03, 2026 For Q2 26
Estimate
-$0.61
Actual
-$1.05
Surprise
-71.57%
FAQ
What were Illumina Inc's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Illumina Inc reported EPS of $1.35, beating estimates by 8.01%, and revenue of $1.16B, 3.05% above expectations.
How did the market react to Illumina Inc's Q4 2025 earnings?
The stock price moved down -10.4%, changed from $133.61 before the earnings release to $119.72 the day after.
When is Illumina Inc expected to report next?
The next earning report is scheduled for May 06, 2026.
What are the forecasts for Illumina Inc's next earnings report?
Based on 18
analysts, Illumina Inc is expected to report EPS of $1.15 and revenue of $1.08B for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement